Last reviewed · How we verify
Detemir insulin
Detemir insulin is a long-acting basal insulin that binds to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in cells.
Detemir insulin is a long-acting basal insulin that binds to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in cells. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Detemir insulin |
|---|---|
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | Basal insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Detemir is a modified human insulin analog with a fatty acid chain attached, which allows it to bind to albumin in the bloodstream and be released slowly, providing a steady basal insulin level over approximately 24 hours. It works by activating insulin receptors on muscle, fat, and liver cells to increase glucose uptake and reduce hepatic glucose production, thereby lowering blood glucose levels in diabetic patients.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Insulin Detemir in Obesity Management (NA)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes (PHASE1)
- Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER) (PHASE4)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
- The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Detemir insulin CI brief — competitive landscape report
- Detemir insulin updates RSS · CI watch RSS
- The University of Texas Health Science Center, Houston portfolio CI